AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00545415 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Order 5
Description: Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out.
Study NCT00545415 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Order 6
Description: Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out.
Study NCT03414541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS102
Description: DS102
Study NCT03414541 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00763997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dipyrone
Description: Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
Study NCT00763997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
Study NCT00763997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
Study NCT00763997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day
Study NCT00763997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parecoxib/Valdecoxib
Description: 40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
Study NCT00763997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
Study NCT00763997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
Study NCT00763997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples
Description: Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
Study NCT04406922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized cooling protocol
Description: As an intervention, a personalized cooling protocol will be used in order to activate BAT and induce non-shivering thermogenesis. During the cooling procedure, subjects will be exposed to mild cold (approx. 14°C) for 150 min. Since the onset temperature of shivering shows a high interindividual variation, we will use a personal cooling protocol to ensure maximum non-shivering EE (and thus an equal maximum activation of BAT). The right temperature will be determined via a subjective method, e.g. to ask the subject if he or she experiences shivering. The time needed to achieve the right temperature is approximately 30-60 minutes. Then, the stable cooling period of 90 min is started. During this time the subject will be asked every 15 minutes whether he is experiencing shivering. If so, temperature will be increased with 2-3°C so that shivering just stops.
Study NCT00533819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 months of healthy physical activity
Description: half an hour of healthy physical activity including 20 minutes aerobic, 5 minutes warm up and cool down, 4 days a week
Study NCT04369833 — intervention group
Intervention type: DEVICE
Intervention: continuous glucose monitoring system
Description: wearing continuous glucose monitoring device (iPro2 professional continuous glucose monitoring, MedtronicⓇ, California, USA)
Study NCT02532374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicorette® inhalator
Description: Subjects will inhale the Nicorette® inhalator (15 mg) at the rate of one deep inhalation every 15 seconds on average, over approximately 20 minutes (80 inhalations in total).
Study NCT02532374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P3L
Description: Subjects will inhale P3L (50 µg/puff, 80 µg/puff and 150 µg/puff) at the rate of one inhalation every 30 seconds on average, over approximately 6 minutes (i.e., 12 inhalations in total).
Study NCT01153217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch from tenofovir to abacavir
Description: Switch from tenofovir to abacavir
Study NCT03136718 — intervention group
Intervention type: OTHER
Intervention: Mobile-enabled RLOs (mRLOs)
Description: A theoretically-driven, personalised educational intervention delivered through mobile technologies based on the C2Hear (https://www.youtube.com/C2HearOnline) RLOs. The mRLO intervention will include shorter 'bite-sized' RLOs suitable for mobile technologies. This will allow a unique dynamic tailoring approach, whereby relevant mRLOs will be provided based on the user's responses to a self-evaluation filter aid, which will enable individualised, tailored learning.
Study NCT03141112 — intervention group
Intervention type: PROCEDURE
Intervention: renal replacement therapy
Study NCT03904420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Education and Treatment Model
Description: Patients will have self directed equipment education and standardized programming approaches
Study NCT03904420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Model
Description: Standard clinical practice and education
Study NCT04135482 — intervention group
Intervention type: OTHER
Intervention: colonic tissue biopsy
Description: colonic tissue biospy of patients with severe crohn's disease using colonoscopy
Study NCT01508247 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated vaccine (Vero Cell) against EV71
Description: inactivated vaccine (vero cell) against EV71, 320U /0.5ml, two doses, on day0, 28
Study NCT01508247 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo, two doses, on day0, 28
Study NCT01089127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study NCT01089127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol 50 μg
Description: Salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
Study NCT01089127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study NCT01089127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study NCT01089127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to salmeterol
Description: Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
Study NCT01089127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to salmeterol
Description: Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
Study NCT03210493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group
Study NCT05869370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity resistance training
Description: Twelve weeks of resistance training twice a week.
Study NCT05869370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity resistance training combined with blood flow restriction
Description: Twelve weeks of resistance training with blood flow restriction twice a week.
Study NCT02048150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-PSMA monoclonal antibody MDX1201-A488
Description: Given IV
Study NCT02048150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo RALP
Study NCT02048150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diffuse optical imaging
Description: Undergo IOOI
Study NCT02048150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02048150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker
Description: Correlative studies
Study NCT02048150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies
Study NCT00317746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Study NCT00317746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT03299101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Prehabilitation will last 4 weeks and consist of a novel, home-based regimen of (a) aerobic conditioning; (b) strength and coordination training; (c) respiratory muscle training; and (d) nutritional coaching and supplementation.
Study NCT04584515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297 40 mg
Description: IMP4297 40 mg: IMP4297 alone, Itraconazole + IMP4297
Study NCT04584515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297 100 mg
Description: IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297
Study NCT03050177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib Tablet 250mg of Hunan Kelun
Description: Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered under fed conditions after a 10-hour overnight fast.
Study NCT02852356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRI-TL Incubator
Description: MIRI-TL Timelapse incubator
Study NCT03050177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib Tablet 250mg of Hunan Kelun
Description: Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered under fed conditions after a 10-hour overnight fast.
Study NCT03050177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iressa® Tablet 250mg of AZN
Description: Single dose of Iressa® Tablet 250mg of AZN was administered under fed conditions after a 10-hour overnight fast.
Study NCT03191513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Interesterified blend of palm kernal and plam stearin
Description: 50 g fat provided as interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
Study NCT03191513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Un-interesterified blend of palm kernal and plam stearin
Description: 50 g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
Study NCT03191513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rapeseed oil
Description: 50 g fat provided as rapeseed oil in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
Study NCT00006501 — intervention group
Intervention type: PROCEDURE
Intervention: ECG
Description: A diagnostic tool that is routinely used to assess the electrical and muscular functions of the heart (non-experimental).
Study NCT02737826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Initiation - Phase I
Description: In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an 8 hour induction window.
Study NCT02737826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin + Buprenorphine - Phase II
Description: Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
Study NCT02737826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Buprenorphine - Phase II
Description: Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
Study NCT02737826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine taper - Phase II
Description: After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
Study NCT01349153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook-based Messages/Website
Description: Twelve weekly messages, a pedometer, sixteen group discussions, and access to an exercise website to promote increased physical activity.
Study NCT03050177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iressa® Tablet 250mg of AZN
Description: Single dose of Iressa® Tablet 250mg of AZN was administered under fed conditions after a 10-hour overnight fast.
Study NCT01525966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01525966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study NCT01525966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00741312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular aerobic physical exercise
Description: Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.~The exercise-program follows the ACOG and ACSM exercise prescription. Aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate) measured by the 6-20 Borg's rating scale. Each session starts with a 5 minutes of warm up, followed by 30 minutes of aerobic activity, including 5 minutes cool down. This is followed by 15 minutes of circuit strength training of the upper limbs, lower limbs, and deep abdominal stabilization muscles. The last 5 minutes consists of stretching and relaxation exercises.
Study NCT00741312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activities of daily living
Description: Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist.
Study NCT04214522 — intervention group
Intervention type: BEHAVIORAL
Intervention: Determine what the imagery levels are
Description: Determine the motor imagery: kinesthetic and visual imagery
Study NCT02137941 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: techniques to optimize potential (TOP)
Description: The TOP consists of learning easy techniques in mental skills to improve cognitive-based problem-solving using respiration, relaxation, and visualization.
Study NCT02137941 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: heart coherence (HC)
Description: The heart coherence (HC) is based on the fact that the heart rhythm becomes more erratic with negative emotions such as anger and anxiety, and more ordered/coherent with sustained positive emotions such as appreciation, love, or compassion, leading to optimal performance and well-being. The HC program uses feedback from a simple pulse sensor to reflect changes of the emotional/psychological state, and to learn how to reduce stress and stabilize emotions.
Study NCT02862080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cathode tsDCS
Description: Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
Study NCT02862080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso
Description: Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.
Study NCT01349153 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facebook-based Self-help Comparison
Description: Twelve weekly messages and a pedometer.
Study NCT00557557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: 5-FU
Description: Dose escalation (200 to 900 mg/m²) scheme, one hour isolated hepatic perfusion prior to standard treatment.
Study NCT00557557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Oxaliplatin
Description: 40 mg/m², one hour isolated hepatic perfusion prior to standard treatment.
Study NCT03388268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vancomycin
Description: Oral vancomycin 125mg 4 times per day
Study NCT03388268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar liquid manufactured to mimic oral vancomycin 125mg
Study NCT03388268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toxin enzyme immunoassay
Description: EIA assay: Wampole/Tech Lab Tox A/B II
Study NCT03388268 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Toxin enzyme immunoassay
Description: EIA assay: Wampole/Tech Lab Tox A/B II
Study NCT03388268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nuceleic acid amplification test
Description: NAAT: Xpert C. difficile, Cepheid
Study NCT03388268 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nuceleic acid amplification test
Description: NAAT: Xpert C. difficile, Cepheid
Study NCT02226861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34 selection system
Description: Stem cells will be selected with the CliniMACS system before transplant.
Study NCT02226861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ULD IL-2
Description: sterile, white to off-white, preservative-free, lyophilized powder suitable for IV infusion upon reconstitution and dilution
Study NCT01484431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil- Tablet or Oral suspension
Description: Tadalafil Tablets administered orally. Tadalafil Oral suspension: An aqueous, ready-to-use suspension for oral administration.
Study NCT01612598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo PCI
Study NCT01612598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01612598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01612598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo PCI
Study NCT01516255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
Study NCT01516255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liraglutide
Description: 0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
Study NCT01516255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
Study NCT01516255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injected subcutaneously. Subjects are randomly allocated to two treatment sequences